Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine added to matrix program for methamphetamine dependence
IRCT20090801002266N16Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of amantadine in methamphetamine use disorder (MUD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Relapse frequency and Craving score. Started Mar 2022; status: completed.
02
Drugs
amantadine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20090801002266N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N16.